Table 4 Researches of ctDNA detection of EGFR mutation and other targeted alterations in NSCLC.
Patients No. | Material | Methods | Dectected genes | EGFR positivity rate in ctDNA | EGFR positivity rate in tissue DNA | Sensitivity | Specificity | Correpondence rate | Year/Ref |
|---|---|---|---|---|---|---|---|---|---|
230 | Plasma | DHPLC | EGFR exon 18–21 | 34.3% | 33.5% | 81.8% | 89.5% | 87.0% | 200932 |
56 | Plasma | qPCR | EGFR exon 18–21 | 23.2% | NA | NA | NA | NA | 201033 |
58 | Serum | Mutant-enriched PCR | EGFR exon19 + L858R | 24.1% | 31.0% | 77.8% | 100.0% | 93.1% | 201134 |
86 | Serum | ARMS-PCR | EGFR exon 18–21 | 25.6% | 59.3% | 43.1% | 100.0% | 66.3% | 201235 |
264 | Plasma | DHPLC | EGFR exon 18–21 | 34.5% | 34.9%* (22/63) | NA | NA | NA | 201236 |
627 | Plasma | mutant-enriched liquidchip | EGFR exon 19 + L858R | 22.0% | 35.6%*(21/59) | NA | NA | NA | 201237 |
111 | Plasma | Mutant-enriched PCR and sequencing | EGFR exon19 + L858R | 17.1% | 40.5% | 35.6% | 95.5% | 71.2% | 201338 |
86 | Plasma | ARMS | EGFR exon18–21 | 31.4% | 46.5% | 67.5% | 100% | 84.9% | 20133 |
57 | Serum | PNA-LNA PCR clamp | EGFR exon 18–21 | 19.3% | 21.1% | 66.7% | 93.3% | 87.7% | 201339 |
94 | Plasma | Scorpion-ARMS | EGFR exon18–21 | 20.2% | 40.4% | 50.0% | 100.0% | 79.8% | 201540 |
121 | Plasma | Mutant-enriched PCR and DHPLC | EGFR exon19, 21 | 34.7% | 36.4% | 77.3% | 89.6% | 85.1% | 201610 |
102 | Plasma | NGS | 70-gene panel | 18.6% | 23.5% | NA | NA | 79.0% | 201612 |
117 | Plasma | Digital PCR | EGFR T790M | 47.0%** | NA | NA | NA | NA | 201641 |
